Abstract: BRAF gene mutations play an important role in the occurrence and development of melanoma. The BRAF mutation rate in Chinese melanoma patients is 25.9% and the most common mutation is V600E. Melanoma patients with BRAF mutations have a poorer prognosis than those with wild-type BRAF. In recent years, with the discovery of new targeted agents and immunotherapeutic drugs, including BRAF inhibitors, MEK inhibitors, programmed death receptor-1 (PD-1)/programmed death receptor-ligand 1 (PD-L1) inhibitors, and cytotoxic T-lymphocyte antigen- 4 (CTLA-4) inhibitors, major progress has been made in the development of adjuvant and systemic treatments for BRAF V600-mutated melanoma. This paper reviews the research progress on the treatment of BRAF-mutated melanoma.